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       ABSTRACT 
BACKGROUND AND PURPOSE: 
 Vitamin B 12 is an essential micro nutrient, required for optimal hemopoietic, 
neurologic and cardio vascular function. Auto immune destruction of insulin 
producing beta cells can produce type 1 diabetes and it’s characterized by the 
presence of insulitis and beta cell auto antibodies. Auto immune gastritis and 
pernicious anemia are common auto immune diseases present in about 2 % of the 
population. This prevalence increases to 3 to 5 fold in type 1 diabetes. Presence of 
parietal cell antibodies and anti-bodies to intrinsic factor has been demonstrated in 
this population. These factors could contribute to the occurrence of B12 deficiency 
in these patients.  
METHODS: 
  In our study about 50 patients with type 1 diabetes mellitus were compared 
with 50 age and sex matched controls and prevalence of vitamin B12 deficiency was 
assessed. Presence of anti-intrinsic factor antibody was done in those deficient in 
vitamin B12. 
RESULTS: 
Our study showed that the prevalence of low serum vitamin B12 in type 1 
diabetics when compared with age and sex matched controls. 42 % of type 1 diabetes 
patients had low vitamin B12 level using laboratory cut- off value of 180 pmol/L 
while only 6 % of controls had low vitamin B12 levels(<180 pmol/l). The presence 
of anti-intrinsic factor antibodies in those deficient in vitamin B12 was done. Among 
24 type 1 diabetes mellitus patients who were deficient in vitamin B12 (<180 
pmol/l), 4 patients had anti intrinsic factor antibodies. Among 3 individuals in the 
control group, who were deficient in vitamin B12 (<180 pmol/l), none of them had 
anti intrinsic factor antibodies, which was statistically significant which stresses the 
fact that auto immune pathology  for vitamin  B12 deficiency. 
CONCLUSION: 
 Clinical vitamin B12 deficiency is highly prevalent among patients with type 
1 DM. These findings merit further research on a larger population using additional 
markers to investigate into the cause of deficiency, the factors involved, and benefit 
of B12 supplementation in these patients. Future large and well-designed studies on 
screening for vitamin B12 deficiency, vitamin B12 supplementation and optimal 
supplementation dose among type 1 and type 2 diabetic patients are warranted to 
help guide formulation of guidelines in diabetes clinical care. 
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INTRODUCTION 
Vitamin B 12 is an essential micro nutrient, required for optimal 
hemopoietic, neurologic and cardio vascular function1. Vitamin B 12 is not 
synthesized in the humans and should be provided from animal source. The 
process of absorption of vitamin B12 is a complex process and if disturbed 
can lead deficiency disease of vitamin B12.Vitamin B 12 deficiency diseases 
are known to be associated with auto immune disorders.   
           Auto immune destruction of insulin producing beta cells can produce 
type 1 diabetes and it’s characterized by the presence of insulitis and beta cell 
auto antibodies. It is associated with other autoimmune endocrine disorders 
and auto antibodies leading to the development of autoimmune polyglandular 
syndrome2. 
Auto immune gastritis and pernicious anemia are common auto 
immune diseases present in about 2 % of the population. This prevalence 
increases to 3 to 5 fold In type 1 diabetes3,4,5. Presence of parietal cell 
antibodies and anti-bodies to intrinsic factor has been demonstrated in this 
population6,7. These factors could contribute to the occurrence of B12 
deficiency in these patients. In addition, the dietary habits which vary from 
one population to another could also contribute to the deficiency. 
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This study is done to assess the prevalence of vitamin B 12 deficiency 
in patients with type 1 diabetes and compare with appropriately age and sex 
matched controls. We also try to find out pernicious anemia as the cause of 
vitamin B12 deficiency by testing for the presence of anti-intrinsic factor 
antibodies. 
  
  
 
 
 
AIM AND OBJECTIVES 
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AIM AND OBJECTIVE 
 
• To study the “Prevalence of VITAMIN B12 DEFICIENCY in Type 1 
Diabetes Mellitus”. 
 
• To correlate the prevalence of vitamin B12 deficiency in Type 1 
Diabetes Mellitus with normal population and try to find out pernicious 
anemia as the cause by testing for anti-intrinsic factor antibodies. 
 
 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
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REVIEW OF LITERATURE 
HISTORY OF DIABETES MELLITUS: 
The first historical description of the condition as we know today as 
Diabetes Mellitus occurred in the Ebers Papyrus, a document of the 18th 
Egyptian Dynasty of about 1500 BC. In India it was known as “Sweetness of 
urine” some 1100 years later, and the term 'diabetes' is believed to have been 
used by the Greeks in the 3rd century BC8.The first description is usually 
credited to Aretaeus of Cappadocia in Asia Minor, in the 1st century AD and 
was the first physician to describe this condition formally. He largely defined 
the condition as passing of copious amounts of urine and the loss of body 
flesh8,9. 
           Although diabetes was recognized in various writings (including from 
China), it was Willis in 1674 who re described “sweetness of the urine” and 
made the deduction that this must be secondary to sweetness of the blood8,9.  
Nevertheless, it was another 100 years later it was demonstrated that this 
sweetness was due to excess sugar, and a further 50 years later this was 
recognized as glucose8. 
           It was in the 19th century which saw the major advances in the 
description of diabetes, its dietary management, its biochemistry and the role 
of pancreas in the pathology of diabetes. Indeed a link between chronic 
pancreatitis and diabetes had already been noted at the end of the 18th 
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century but the missing pancreatic factor was made only after the descriptions 
of glycosuria following pancreatectomy in dogs by von Mering and 
Minkowski in 1890.The 19th century also saw the recognition that diabetes 
might not be a single disease, with a different natural history when presenting 
in childhood compared to late adulthood. The first clinical descriptions of 
coma in association with acidosis were also made at this time, and Bernard 
set the biochemical basis of the condition with his observations on the 
production of glucose by the liver 8. 
           Although descriptions of the treatment of diabetes appear in some of 
the very early documents, it is often difficult to appreciate whether the diets 
and herbal remedies offered represent specific therapies or whether they were 
merely parts of the regular therapeutic armory available for serious disease at 
that time. Again it was nearly the 19th century before dietary management 
was formally introduced by Rollo, and throughout that Century a host of 
dietary measures were suggested for the condition8. 
           Towards the end of 19th century the history of diabetes is dominated 
by the observations leading to the isolation of insulin, following the 
discoveries of Minkowski, and the demonstration by Opie of degeneration of 
the islets of Langerhans. Numerous attempts at insulin extraction were 
recorded after 1890, and some of the preparations (for example by De Witt, 
Zuelzer, Paulesco) appear to have had glucose lowering activity. While it 
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seems likely that a therapeutic preparation would have been made in any case 
within a couple of years, it fell to the drive and ideas of Banting, the technical 
support of Best, the facilities and guidance of MacLeod and the biochemical 
expertise of Collip to produce an adequately pure and potent preparation of 
bovine insulin in 19228. 
           Following decades were most clearly marked by the development of 
the extended acting insulin preparations by Hagedorn and Hallas-Moller, and 
the accidental discoveries of the hypoglycaemic effects of the biguanide and 
sulphonylurea groups of drugs. It is yet unclear whether the introduction of 
highly purified insulin preparations, glycosylated haemoglobin estimation, 
self-blood glucose monitoring, islet and pancreas transplantation, insulin 
infusion pumps and genetically engineered insulin will lead to history judging 
the period between 1973 and 1983 as the most significant in the 
understanding and management of diabetes8. 
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TECHNICAL MILESTONES IN THE MANAGEMENT OF 
DIABETES8. 
Year Worker(s) Milestone 
1797 Rollo Dietary management 
1913 Alien Severe calorie restriction 
1921 Banting, Best, Collip, Macleod Isolation and use of insulin 
1936 
Hagedorn and colleagues Protamine-insulin complexes 
used  
1939 Loubatieres Discovery of Sulphonylureas 
1970 
Jorgensen and Colleagues  Highly purified insulin 
available 
1976 
Sonksen and colleagues 
Walford and Colleagues 
Self blood glucose monitoring 
1976 
Koenig and colleagues Glycosylated haemoglobin to 
Monitor control 
1979 Goeddel and colleagues Genetically engineered insulin 
1980 
Many researchers  Microcomputers in diabetes 
management 
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CLASSIFICATION OF DIABETES MELLITUS; 
Diabetes is classified into four main groups based on known 
pathological and etiologic mechanisms-type 1, type 2, other specific types, 
and Gestational diabetes. Type 1 diabetes results from pancreatic islet cell 
destruction most commonly by an autoimmune process. These patients are 
prone to developing ketoacidosis and require insulin replacement. Type 2 
diabetes the most prevalent form of diabetes, is a heterogeneous disorder 
most commonly associated with insulin resistance with or without 
abnormalities of insulin secretion. 
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TABLE 1: CLASSIFICATION OF DIABETES MELLITUS12. 
ETIOLOGICAL 
CLASSIFICATION 
CHARACTERSTICS 
Type 1 A 
Type 1 B 
Immune mediated 
Immune destructive, not auto immune 
Type 2 Insulin resistance +/- insulin 
secretory defects 
Other specific types Mitochondrial, maturity onset 
diabetes of young, endocrinopathies, 
lipo dystrophy, drug induced, 
infections 
              Gestational diabetes  
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TABLE 2:  
DIFFERENCES BETWEEN TYPE 1 AND TYPE 2  
DIABETES MELLITUS 
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TYPE 1 DIABETES MELLITUS; 
Understanding the pathogenesis of type 1 diabetes mellitus (type 1 
DM) is crucial for developing preventive strategies. It is estimated that 50% 
to 90% of type 1 DM patients have evidence of auto-antibodies and they are 
labelled as type 1A DM or autoimmune type 1 DM while the remaining are 
called type 1B DM or idiopathic type 1 DM. The prevalence of type 1B DM 
is reported to be 5% to 10% in Caucasian populations. Though limited data is 
available on type 1 DM from India, in one study as much as 45% of recently 
diagnosed subjects were found to have idiopathic or type 1B DM. Though the 
exact pathophysiology is unknown for this subtype, various factors like viral 
infection, toxins, subclinical pancreatitis or some unidentified genetic defects 
might be responsible10,11. 
 
 
 
  
FIGURE 1:   TEMPORAL ASSOCIATION OF TYPE 1 DIABETES 
MELLITUS  
In subjects who are genetically predisposed to type 1 DM, certain, as 
yet, poorly defined environmental triggers initiate T
response. With the development of insulitis, autoanti
which can be detected long before the development of clinical type 1 DM. 
Insulitis is a slowly progressive disease and over a period of months or years, 
may cause complete destruction of 
manifestation of type 1 DM 
12 
-cell mediated immune 
bodies are produced, 
β-cells (insulinopaenia) leading to clinical 
10,11
. 
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FIGURE 2:  PATHOGENESIS OF TYPE 1 DIABETES MELLITUS 
 
Latent autoimmune diabetes of adulthood (LADA) 23: 
Type 1 diabetes can manifest at any age, although most commonly it 
presents before school age and around puberty. Older adults often present 
with a more indolent onset that sometimes leads to misdiagnosis and has led 
to the use of the term latent autoimmune diabetes of adulthood (LADA) to 
distinguish these patients. These initially unrecognized patients may retain 
enough cell function at the outset to avoid ketoacidosis, but as their beta cell 
mass diminishes they develop increasing dependence on insulin therapy. Islet 
cell antibody studies indicate that up to 15% of patients previously diagnosed 
with type 2 diabetes may actually have LADA 10,11. 
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AUTO IMMUNITY AND TYPE 1 DIABETES MELLITUS: 
Circulating antibodies against cell proteins, islet cell antibodies (ICA), 
insulin autoantibodies (IAA), and antibodies to glutamic acid decarboxylase 
65 (GAD), tyrosine phosphatase IA2 (ICA512), and zinc transporter 8 (ZnT8) 
are present in most patients with type 1 diabetes at diagnosis 15,16,18 .These 
autoreative antibodies can often be detected well before the onset of frank 
hyperglycemia, even decades earlier, providing evidence that the autoimmune 
process may be prolonged. After diagnosis, autoantibody levels often decline 
with increasing duration of the disease. Also, once patients are treated with 
insulin, low levels of IAA develop, even in patients that do not have an 
autoimmune etiology for their diabetes 13. 
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TABLE 3: ANTI BODIES IN TYPE 1 DIABETES MELLITUS17 
 
 
 
Although useful for diagnosing and predicting type 1 diabetes, 
antibodies against beta cell proteins do not directly cause the destruction of 
beta cells in type 1 diabetes. Instead, it is the cellular immune system, the T 
lymphocytes that infiltrate the islets (a process called insulitis) and destroy 
the beta cells. At the time of diagnosis, the islets of patients with type 1 
diabetes are extensively infiltrated with both helper and cytotoxic T 
lymphocytes19,20. Normally, the thymus deletes auto reactive T cells during 
development so that the immune system becomes tolerant of self–antigens. In 
addition, certain specialized T cells, the regulatory T cells, further prevent 
attacks against healthy tissues by retraining the activity of any auto reactive 
cytotoxic and helper T cells that escape the thymus. Type 1 diabetes results 
from a breakdown in these processes of self-tolerance in the immune 
system16,17. 
16 
 
 
 
 
 
FIGURE 3:EFFECTS OF MULTIPLE ISLET AUTOANTIBODIES ON 
THE RISK OF TYPE 1 DIABETES (T1DM) 
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PATHOGENESIS OF TYPE 1 DIABETES MELLITUS: 
Type 1 diabetes constitutes less than 2% of total diabetic population in 
India. In majority of type 1 diabetes patients, there is rapid destruction of β-
cells of pancreas, in a susceptible subject due to viral mediated autoimmune 
process. A typical type 1 diabetes patient is below 30 years, is underweight 
and present with frank symptoms, e.g. polyuria, polydipsia, polyphagia, 
weakness, weight loss, restlessness and if continued for some period, may 
lead to diabetic ketoacidosis with altered sensorium and severe dehydration. 
Occasionally a child with similar clinical presentation in a remote area may 
die before the diagnosis is made. Any comatose child presenting with severe 
dehydration without diarrhea, a diagnosis of type 1 diabetes should be in the 
list of diagnostic consideration. In some type 1 diabetic subjects, β-cell 
destruction is slower and may mimic a type 2 diabetes in clinical presentation 
(latent autoimmune diabetes in adult (LADA)23. After initial treatment with 
insulin, a type 1 diabetic may recover some residual β-cell function (the so-
called ‘honeymoon phase’) when they can be maintained with a small daily 
dose of insulin; rarely, they do not even need insulin for some period of time. 
However, this phase of recovery of residual β-cell function is temporary and 
the autoimmune process ultimately destroys the remaining β-cells and the 
subject becomes completely insulin deficient and require insulin for survival 
13
.   
18 
 
 
GENETICS OF TYPE 1 DIABETES MELLITUS; 
Increased lifetime risk of developing type 1 diabetes is present in 
Family members of patients with type 1 diabetes. The offspring of a mother 
with type 1 diabetes have a risk of 3%, whereas the risk is 6% for children of 
affected fathers. The risk in siblings of affected individuals is related to the 
number of human leukocyte antigen (HLA) haplotypes that the sibling shares 
32-34
. If one haplotype is shared, the risk is 6% and if two haplotypes are 
shared, the risk increases to 12% to 25%. For monozygotic twins, the 
concordance rate reaches 25% to 50%. Although these data demonstrate a 
strong genetic contribution to the risk of type 1 diabetes, genetics plays an 
even larger role in type 2 diabetes, and environment also clearly contributes 
substantially to the risk of type 1 diabetes16,17. 
           Genes in the major histocompatibility (MHC) locus on the short arm 
of chromosome 6 explain at least half of the familial aggregation of type 1 
diabetes. Within the MHC locus lie a number of closely packed genes 
involved in the function and regulation of the immune response. Although a 
number of genes within the MHC locus have been linked to the risk of 
developing type 1 diabetes, the most important of these are the genes 
encoding the HLA class II molecules DQ and DR. The professional antigen-
presenting cells, dendritic cells, macrophages and B lymphocytes, use the 
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class II molecules on their cell surface to present peptide antigens to T 
lymphocytes through the T-cell receptor. T cells activated by antigen-
presenting cells carry out the cell destruction that leads to type 1 diabetes. 
Although exact mechanisms remain uncertain, the variations in the amino 
acid sequence of individual HLA class II molecules may impact their ability 
to present specific self-peptides to T cells either in the process of central or 
peripheral tolerization or later during the development of the autoimmune 
response, thereby contributing to the risk of developing type 1 diabetes16,17. 
The DR Haplotypes DR3 and DR4 are major susceptibility risk factors 
for type 1 diabetes. As many as 95% of type 1 diabetic patients have a DR3 
or a DR4 haplotype—or both—compared with 45% to 50% of Caucasian non 
diabetic controls. Individuals who express both a DR3 and a DR4 allele carry 
the highest risk for type 1 diabetes 24,25. 
           An independent genetic link to chromosome 11 has also been 
identified in type 1 diabetes. Studies of a polymorphic DNA locus flanking 
the 5' region of the insulin gene on chromosome 11 revealed a small but 
statistically significant linkage between type 1 diabetes and this genetic locus. 
This polymorphic locus, which consists of a variable number of tandem 
repeats (VNTRs) with two common sizes in Caucasians, small (26-63 
repeats) or large (140-243 repeats), does not encode a protein27-30. An 
intriguing proposal to explain how the VNTR might influence susceptibility 
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to type 1 diabetes was based on findings that insulin gene transcription is 
facilitated in the fetal thymus gland by the presence of the large allele of the 
VNTR locus flanking the insulin gene. The large VNTR allele might produce 
a dominant protective effect by promoting negative selection (deletion) by the 
thymus of insulin-specific T lymphocytes that play a critical role in the 
immune destruction of pancreatic cells. 
The established genetic association with the MHC region of 
chromosome 6 contributes much more (about 50%) to the genetic 
susceptibility to type 1 diabetes than does this locus flanking the insulin gene 
on chromosome 11, which contributes about 10%. Both candidate gene 
studies and genome-wide association studies (GWAS) have identified a 
number of additional risk loci that make smaller contributions to the genetic 
risk of type 1 diabetes. Many of the genes linked to these additional loci also 
play important roles in the function and regulation of the immune response27-
31
. 
           Mutations in two genes involved in T-cell tolerance cause rare 
syndromes of type 1 diabetes together with other autoimmune diseases. In the 
autosomal recessive disease autoimmune polyglandular syndrome type 1, 
homozygous mutations in the gene encoding the autoimmune regulator 
(AIRE) prevent the expression of certain self-proteins in the thymus, thus 
allowing mature auto reactive T cells to leave the thymus. In addition to other 
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autoimmune diseases and mucocutaneous candidiasis, approximately 20% of 
patients with APS1 develop type 1 diabetes32-34. The second gene, FOXP3, 
found on the X chromosome, encodes a transcription factor required for the 
formation of regulatory T cells. Mutations in FOXP3cause 
immunodysregulationpolyendocrinopathyenteropathy X-linked (IPEX) 
syndrome. IPEX presents in male patients with very early onset type 1 
diabetes, often neonatal, combined with other autoimmune endocrinopathies, 
autoimmune skin disorders, diarrhea secondary to autoimmune enteropathy, 
and frequent severe infections 14. 
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FIGURE 4: NATURAL HISTORY OF TYPE 1 DIABETES. 
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ENVIRONMENTAL FACTORS IN TYPE 1 DIABETES: 
While genetic inheritance may play an important role in causing type 1 
diabetes, the monozygotic twin studies demonstrate that other 
causes,stochastic or environmental, are at least as important. Most individuals 
with type 1 diabetes do not have other family members with the disease. 
vacor (a nitrophenylurea rat poison), spoiled tapioca orcassava root and 
viruses (mumps, congenital rubella, Coxsackie virus B4) have increased risk 
of developing diabetes How these environmental insults lead to type 1 
diabetes is unknown; they may directly damage cells in some cases, or may 
actas initiators or accelerators of the autoimmune attack on the cells 35-41. In 
some cases, molecular mimicry, wherein the immune system 
mistakenlytargets cell proteins that share homologies with certain viral or 
other foreign peptides may play a role. 
Epidemiological studies have demonstrated an association between 
breast-feeding in the first 6 months of life and protection from type 1 
diabetes. While it has been suggested that proteins in cow's milk may be the 
culprits, the strongest evidence supports the idea that human breast milk may 
reduce the risk of autoimmune disease. 
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TABLE 4 : 
 ENVIRONMENTAL RISK FACTORS ASSOCIATED WITH  
TYPE 1 DIABETES MELLITUS (T 1 DM). 
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Accumulating evidence shows that in the process of modernizing and 
improving public health, the risk of type 1 diabetes has increased, possibly 
due to the removal of some protective factors. Type 1 diabetes is almost 
unheard of in many third-world countries, and has its highest incidence in 
countries with the best public health systems, such as the Scandinavian 
countries. In addition, the incidence of the disease has been steadily 
increasing over the past century in western and westernizing countries and is 
especially high among the more affluent. This has led to the suggestion that a 
dirty environment, one with more infections (especially more parasitic 
diseases) and more antigen exposure, may reduce the risk of type 1 
disease35,41. 
CLINICAL FEATURE OF TYPE 1 DIABETES MELLITUS: 
Patients with type 1 diabetes present with symptoms and signs related 
to hyperglycemia and hyperketonemia. The severity of the insulin deficiency 
and the acuteness with which the catabolic state develops determine the 
intensity of the osmotic and ketotic excess. 
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FIGURE 5:  
EFFECT OF INSULIN DEFICIENCY ON  
BODY FUEL METABOLISM 
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DIAGNOSIS OF DIABETES:  
TABLE 5: DIAGNOSIS OF DIABETES MELLITUS12 
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STAGES OF DIABETES  
Stages of diabetes range from normal glucose tolerance through 
impaired glucose tolerance and impaired fasting glucose, into frank diabetes 
mellitus, which may be non-insulin requiring, insulin requiring for survival. 
Type 1 DM can be found across the whole spectrum. In the early stages of 
treatment there can be a period of non- insulin requirement, but later followed 
by insulin requirement for survival. In type 2 DM, insulin may be required 
during a period of ketoacidosis precipitated by severe stress or infection. 
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FIGURE 6:  
CLASSIFICATION OF DIABETES MELLITUS 
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COMPLICATIONS OF DIABETES59-61: 
Eyes 
• Diabetic retinopathy 
o Nonproliferative (background) 
o Proliferative 
• Cataracts 
o Subcapsular (snowflake) 
• Nuclear (senile) 
 
Kidneys 
• Intercapillaryglomerulosclerosis 
o Diffuse 
o Nodular 
• Infection 
o Pyelonephritis 
o Perinephric abscess 
o Renal papillary necrosis 
• Renal tubular necrosis 
o Following dye studies (urograms, arteriograms) 
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Nervous System 
• Peripheral neuropathy 
o Distal, symmetric sensory loss 
• Motor neuropathy 
o Foot drop, wrist drop  
o Mononeuropathy multiplex (diabetic amyotrophy) 
o Cranial neuropathy 
o Cranial nerves III, IV, VI, VII 
• Autonomic neuropathy 
o Postural hypotension 
o Resting tachycardia 
o Loss of sweating 
o Gastrointestinal neuropathy 
o Gastroparesis 
o Diabetic diarrhea 
o Urinary bladder atony 
o Impotence (may also be secondary to pelvic vascular disease). 
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Skin 
• Diabetic dermopathy (shin spots) 
• Necrobiosislipoidicadiabeticorum 
• Candidiasis 
• Foot and leg ulcers 
o Neurotropic 
o Ischemic 
 
Cardiovascular System 
• Heart disease 
o Myocardial infarction 
o Cardiomyopathy 
• Peripheral vascular disease 
o Ischemic ulcers: gangrene 
• Cerebrovascular disease 
 
Bones and Joints 
• Diabetic cheiroarthropathy 
• Dupuytren contracture 
• Charcot joint 
• Osteomyelitis 
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FIGURE 7:  
PATHWAYS TO FOOT ULCERATION IN DIABETES 
 
Unusual Infections 
• Necrotizing fasciitis 
• Necrotizing myositis 
• Mucor meningitis 
• Emphysematous cholecystitis 
• Malignant otitis externa  
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PREVALENCE OF CHRONIC COMPLICATIONS BY TYPE OF 
DIABETES:  
Although all of the known complications of diabetes can be found in 
both types of the disease, some are more common in one type than in the 
other. ESRD occurs more commonly in type 1 diabetic individuals when 
compared with type 2 diabetes individuals. .proliferative retinopathy causes 
blindness in type 1, whereas macular edema and ischemia are the usual cause 
in type 2. Similarly, although diabetic neuropathy is common in both type 1 
and type 2 diabetes, severe autonomic neuropathy with gastroparesis, diabetic 
diarrhea, resting tachycardia, and postural hypotension is much more 
common in type 1. 
 
PATHOGENESIS OF CHRONIC COMPLICATIONS: 
Though hyperglycemia is an important factor, the mechanism of such 
diverse cellular and organ dysfunction is unknown. Four Prominent theories 
have been proposed43-58. 
 
 
 
35 
 
 
 
AGEs Theory 
Increased intra-cellular glucose causes non enzymatic glycosylation of 
intra- and extra-cellular proteins by interaction of glucose with amino acid 
groups on proteins, resulting in formation of advanced glycosylation end 
products (AGEs). Serum levels of AGEs correlates with the level of 
glycaemia and these products accumulate as glomerular filtration rate 
declines. Interaction of AGEs with the receptors in mesangial cells leads to 
increased transforming growth factor β (TGF-β) expression and extra-cellular 
matrix synthesis. Aminoguanidine, a compound that inhibits AGEs, was 
useful in experimental studies but resulted in occurrence of ANCA positive 
vasculitis and is not approved for clinical use 48,49,50. 
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FIGURE 8: 
INCREASED PRODUCTION OF INTRACELLULAR ADVANCED 
GLYCATION END - PRODUCTS (AGE) PRECURSORS 
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SORBITOL PATHWAY (POLYOL PATHWAY): 
Some glucose is converted to sorbitol by the enzyme aldose reductase 
when the amount of Intra-cellular glucose metabolized by phosphorylation 
and subsequent glycolysis, is increased. Redox potential is altered by 
increased sorbitol concentration which alters cellular osmolality, generates 
reactive oxygen species and increases AGEs formation, and likely and causes 
cellular dysfunction. Cataract formation and neuropathy and retinopathy to 
some extent have been linked to this pathway. Newer aldose reductase 
inhibitors like fidarestat are undergoing clinical trials, epelrestat has been 
approved for use51,53. 
 
FIGURE 9:  
POLYOL PATHWAY 
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PROTEIN KINASE C PATHWAY: 
Hyperglycaemia increases formation of diacylglycerol, leadingto 
activation of protein kinase C (PKC). PKC is a family of serinethreonine 
kinases that alter the transcription of genes forfibronectin, type IV collagen, 
contractile proteins and extracellular matrix protein in endothelial cells and 
neurons.. PKCmediates TGF-β1, angiotensin-II and vascular 
endothelialgrowth factor (VEGF) and modulates mitogen activated 
proteinkinase (MAPK), which mediates sclerosis. Inhibitors of PKC-b 
likeruboxistaurinmesylate that reduce the direct cellular actionsof AGEs, 
VEGF, Endothelin-1, reduce oxidised lipids and oxidantproduction, are being 
studied in clinical trials in diabetesmellitus (DM) for retinopathy and 
neuropathy57. 
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FIGURE 10:  
ACTIVATION OF PROTEIN KINASE C (PKC) BY DE NOVO 
SYNTHESIS OF DIACYLGLYCEROL (DAG) AND SOME OF ITS 
PATHOLOGIC CONSEQUENCES 
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HEXOSAMINE PATHWAY: 
Hexosamine pathway, generates fructose-6-phosphate, which is 
increased by hyperglycemia. Hexosamine pathway alters the function by 
causing glycosylation of proteins, such as endothelial nitric oxide synthase, or 
by changing gene expression of transforming growth factor β (TGF-β) or 
plasminogen activator inhibitor-1 (PAI-1) 55, 56. 
 
FIGURE 11: HEXOSAMINE PATHWAY 
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GROWTH FACTORS : 
VEGF-A is increased locally indiabetic proliferative retinopathy and 
decreases after laserphotocoagulation. Inhibition of angiotensin-II also 
reduces VEGF,which could explain one of the beneficial effects of 
angiotensinII receptor blockers on microangiopathic diseases. 
Monoclonalantibodies to VEGF like ranibizumab in experimental studies 
have shown improvement in proliferative diabetic retinopathy. Other growth 
factors, such as “platelet derived growth factor, epidermal growth factor, 
insulin like growth factor, growth hormone, basic fibroblast growth factor, 
connective tissue growth factor and even insulin”, have been suggested to 
play a role in DM related complications. 
 
GLYCEMIC CONTROL AND COMPLICATIONS: 
Reduction in chronic hyperglycaemia canprevent many early 
complications of type 1 DM. as suggested by “The diabetes control and 
complications trial (DCCT) “. This largemulticentre clinical trial randomized 
1,400 type 1 diabetics toeither intensive or conventional diabetes 
management andprospectively evaluated the development of 
retinopathy,nephropathy, and neuropathy. The intensive group achieved 
asubstantially lower HbA1c (7.3%) than the conventionallymanaged group 
(9.1%).DCCT showed that improvement of glycaemic control reducednon-
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proliferative and proliferative retinopathy by 47%,microalbuminuria by 39%, 
and clinical nephropathy by 54% andneuropathy by 60%. Improved 
glycaemic control also slowedthe progression of early diabetic complications. 
A nonsignificant trend in reduction of macro vascular events wasobserved 
during the trial (most individuals were young, with allow risk of 
cardiovascular disease). Results of DCCT predictedthat type-1 diabetics with 
intensive management gain 7.7additional years of vision, 5.8 additional years 
free from ESRDand 5.6 additional years free from lower limb amputations. If 
allthe complications were combined, intensively managed group would 
experience 15.3 more years of life without significant micro vascular or 
neurological complications of diabetes as compared to diabetics receiving 
standard therapy 63. 
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FIGURE 12: SUMMARY OF RESULT OF DCCT63 
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TREATMENT: 
Replacement therapy with exogenous insulin. Is required for all 
patients with type 1 diabetes mellitus. At the onset of type 1 diabetes, many 
patients recover some pancreatic cell function and may temporarily need only 
low doses of exogenousinsulin to supplement their own endogenous insulin 
secretion. This is known as the honeymoon period. Within 8 weeks to 2 
years, however,most of these patients show either absent or negligible 
pancreatic cell function62.  
At this point, these patients should be switched to a moreflexible 
insulin regimen with a combination of rapid-acting insulin analogs or regular 
insulin together with intermediate-acting or long-actinginsulin. At a 
minimum, the patient should be on a three-injection regimen and frequently 
may need four or more injections. Twice-daily split dose insulin mixtures 
cannot maintain near normalization of blood glucose without hypoglycemia 
(particularly at night) and are not recommended. Self-monitoring of blood 
glucose levels is required for determining the optimal adjustment of insulin 
dosage and the modulationof food intake and exercise in type 1 diabetes. 
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TABLE 6: DIFFERENT TYPES OF INSULIN 
 
 
Certain caveats should be kept in mind regarding insulin treatment. 
Considerable variations in absorption and bioavailability exist, even when the 
same dose is injected in the same region on different days in the same 
individual. Such variation often can be minimized by injecting smaller 
quantities of insulin at each injection and consequently using multiple 
injections. Furthermore, a given insulin dosage may demonstrate considerable 
variability in pharmacokinetics in different individuals, either because of 
insulin antibodies that bind insulin with different avidity or for other as yet 
unknown reasons. A properly educated patient should be taught to adjust 
insulin dosage by observing the pattern of recorded self-monitored blood 
glucose levels and correlating it with the approximate duration of action and 
the time to peak effect after injection of the various insulin preparations. 
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A combination of rapid-acting insulin analogs and long-acting insulin’s 
(insulin glaring or insulin detemir) allows for more physiologic insulin 
replacement. In clinical studies, combinations of rapid-acting insulin analogs 
(insulin lispro or insulin aspart) with meals together with intermediate-acting 
(NPH) or longer acting insulin (insulin glargine) for basal coverage have now 
been shown to have improved HbA 1c values62. 
 
VITAMINS: 
Vitamin is derived from the Latin word vita =life, Amin=amine. It was 
named by casimir funk who thought that these substances were amines .The 
term vitamin is defined as “a group of substances that are essential, in small 
quantities, for the normal functioning of metabolism in the body”. Vitamins 
are mainly divided into two groups: water soluble (vitamins B-complex and 
C) and fat-soluble (A, D, E and K).Unlike water-soluble vitamins that need 
regular replacement in the body, fat-soluble vitamins can be stored for long 
periods in the human body in liver and fatty tissues and are eliminated much 
more slowly than water-soluble vitamins. 
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VITAMIN B 12: 
The discovery of vitamin B12 dates back to   1926, when, Murphy and 
Minot, based on Whipple’s observation that anemic dogs could be cured by 
feeding them raw liver, discovered that pernicious anemia could be treated by 
supplementing the human diet with liver. After this observation, an intensive 
search for the "liver factor" was started. It was only, in 1948, when the “anti-
pernicious anemia factor”, which became called Vitamin B12, was finally 
purified and isolated by Folkers and his co-workers, and by Smith and Parker. 
Its importance is stressed by the fact that Whipple, murphy and Minot were 
awarded Nobel Prize in 1934 for their discovery64. 
           Vitamin B 12 is an essential co factor that plays an important role in 
methylation of DNA that is integral for DNA synthesis and cellular 
metabolism. Its deficiency affects cellular metabolism and can lead to serious 
clinical consequences.1 
 
BIOCHEMISTRY OF VITAMIN B 12; 
Vitamin B12 is water soluble, heat stable and red in color. It contains 
4.35% cobalt by weight. It contains one cobalt atom. Four pyrrole rings 
coordinated with a cobalt atom is called a Corrin ring. . The 5th valencyof the 
cobalt is covalently linked to a substituted benzimidazole ring. This is then 
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called cobalamin. The 6thvalency of the cobalt is satisfied by any of the 
following groups: cyanide, hydroxyl, adenosyl or methyl. 
a. Cyanocobalamin 
When cyanide is added at the R position, the molecule is called 
cyanocobalamin. During the isolation procedure, cyanide is added to get 
stablecrystals. The CN group has no physiological function, it is only a 
laboratory artefact. Oral preparations are in this form. 
b. Hydroxycobalamin 
When hydroxyl group is attached at the R position, it is called 
hydroxycobalamin or vitamin B12a.Injectable preparations are in this form. 
c. Adenosylcobalamin (Ado-B12) 
When taken up by the cells, these groups are removed and 
deoxyadenosylcobalamin or AdoB12 is formed. This is the major storage 
form, seen in liver. 
d. Methyl cobalamin 
When the methyl group replaces adenosyl group, it is known as methyl 
cobalamin. This is the major form seen in blood circulation as well as in 
cytoplasm of cells. The Ado-B12and methyl B12are the functional co-
enzymes in the body. 
  
 
FIGURE 13: CHEMICAL STRUTURE OF VITAMIN B 12
 
Biochemical functions of vitamin B12
             Vitamin B 12 serves as a co factor in two important bio chemical 
reaction76,79. 
A)  remethylation of homocysteine to form methionine.
B) Isomerization of methylmalonyl CoA.
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 ROLE OF VITAMIN B12 
METHYLMALONIC ACID M
 
REMETHYLATION OF HOMOCYSTE
METHIONINE: 
Vitamin B12 is the cofactor through which the methyl group of N5
methyl-TH4 is transferred to homocysteine to regenerate methionine. 
Vitamin B12 is active in its reduced form, Cobalamin. The catalytic activity 
of methionine synthase is regenerated by methionine synthase reductase, 
which uses S- adenosylmethionine to catalyze the reductive methylation of 
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FIGURE 14:  
IN HOMOCYSTEINE AND 
ETABOLISM
INE TO FORM 
 
 
-
 vitamin BI2.In most cells, N5
synthesis of methyl- B 12.
CONVERSION OF HOMOCYSTEINE TO METHIONINE
 
ISOMERIZATION OF MET
Deoxyadenosyl-B 12 is a cofactor for methylmalonyl
which catalyzes the conversion of methylmalonylcoA to succinylcoA. This 
reaction is a key component of the pathway by which the carbon skeleton of 
Propionyl-CoA is metabolized.  Propionyl
odd-chain fatty  
Acids are oxidized and during the catabolism of the carbon skeletons 
of valine,  
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-methyl-TH4 is the only methyl donor for the 
 
FIGURE 15:  
HYLMALONYL COA: 
-CoA is generated when 
 
 
-CoA mutase, 
 
 Isoleucine, and cysteine. Subsequent metabolism of succinyl
of the TCA cycle generates oxaloacetate, which can be used to synth
glucose.   
FIGURE 16: ISOMERIZATION OF METHYL MALONYL COA
PHYSIOLOGY OF VITAMIN B12 
For adults, the Recommended Dietary Allowance for Cobalamin is 2 
mcg/day, for pregnant and lactating women, the RDA is 2.6 mcg/day. For 
children, the RDA for Cb
to 2 mcg/day during adolescence. Similarly, if a patient with successfully 
treated pernicious anemia stops taking B12, it will take the same time 
(approximately three years) for the deficiency to recur.
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66; 
l ranges from 0.7 mcg/day during the toddler stage 
 
-CoA by means 
esize 
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Utilization of dietary vitamin B12 is dependent on both gastric HC1 
and two specialized proteins, R proteins and intrinsic factor. Dietary vitamin 
B 12 is covalently bound to polypeptides; release of vitamin B 12 normally 
occurs in the stomach through the combined hydrolytic actions of HC1 and 
pepsin. R proteins (also designated huptocorrins or cobalophilins) are present 
in both saliva and gastric juice. They bind the vitamin B12 prior to its release 
from the polypeptides, and remain associated with vitamin B12 until the R 
proteins are hydrolyzed in the small intestine.  
           Intrinsic factor (IF), a glycoprotein produced by the parietal cells of 
the stomach, is essential for the absorption of vitamin B12. Intrinsic factor is 
so named because early studies demonstrated that both a dietary (extrinsic) 
factor and a protein produced by the normal stomach (intrinsic) were 
necessary for the prevention of pernicious anemia. As soon as vitamin Bl2 is 
released from the R proteins, it binds to intrinsic factor. The IF-B 12 complex 
is then recognized by specific receptors, called cubulins, located primarily in 
the distal ileum. The major protein that transports vitamin B12 from the 
intestine to other tissues is transcobalamin 11, which is a member of the R-
protein family 66, 67,73. 
            Electron microscopic studies have shown colocalization of cubilin 
with the endocytic proteins megalin and "amnionless" (AMN), which may 
mediate vesicular trafficking of the complex via a calcium-dependent 
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mechanism. It is likely that the functional ileal receptor for the cobalamin-
intrinsic factor complex is a complex of AMN and cubilin. 
Mutations in either the cubilin or the AMN gene cause hereditary 
megaloblastic anemia, while absence of megalin has been associated with 
failure of normal renal tubular reabsorption of the Cbl-transcobalamin 
complex in mice. 
Thus, absorption of cobalamin depends upon five factors, 
• Adequate dietary intake 
• Acid-pepsin  
• Pancreatic proteases 
•  functional intrinsic factor(in stomach) 
•  functioning Cbl-IF receptors (in ileum) 
 
The need for an intact upper GI tract for effective absorption of cobalamin 
was shown in a report of patients receiving a Roux-en-Y gastric bypass for 
morbid obesity. Standard multivitamin preparations were inadequate to 
maintain vitamin B12, folic acid, iron, calcium, and vitamin D levels80-84. 
 FIGURE 17: ABSORPTION OF VITAMIN B 12
After being taken up by ileal enterocytes, Cobalamin is exported via 
the ATP-binding cassette (ABC)
multidrug resistance protein, MRP1), present in the basolateral membrane of 
intestinal epithelium and other cells.  Coba
transcobalamines: TC I, II, and III. Up to 80 percent of Cobalamin is bound 
to TC I and III, which have no identified role in Cobalamin metabolism. It is 
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-drug transporter ABCC1 (also called 
lamin enters plasma bound to three 
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the TC II-Cbl complex that is physiologically important. The three-
dimensional structure of transcobalamin shows that there are two domains for 
binding cobalamin. This complex has a half-life of six to nine minutes and 
binds to specific cell surface receptors from which it enters cells by receptor 
mediated endocytosis. cobalamin in the cells is metabolized into two 
coenzymes: adenosyl-Cbl; and methyl-Cbl, the functions of which are 
described above. 
Transcobalamin II has a common polymorphism, in which proline 
replaces arginine at codon 259. In one study, normal older adults 
homozygous or heterozygous for the proline polymorphism had higher levels 
of HoloTCII and lower levels of methylmalonic acid than those homozygous 
for the arginine form, suggesting that the former may be more efficient in 
delivering cobalamin to tissues . It is not known whether the TCII genotype 
influences susceptibility for development of clinical manifestations of 
cobalamin deficiency. 
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FIGURE 18: ABSORPTION AND METABOLISM OF VITAMIN B 12 
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CAUSES OF VITAMIN B 12 DEFICIENCY73-77; 
Impaired gastric absorption 
•Pernicious anemia 
• Gastrectomy—partial or total 
• Zollinger-Ellison syndrome 
Impaired intestinal absorption; 
• Ileal resection or disease—for example, Crohn’s inflammatory bowel 
disease and tuberculous ileitis 
• Blind loop syndrome 
• Luminal disturbances: chronic pancreatic disease and gastrinoma 
• Parasites: giardiasis, bacterial overgrowth, and fish tapeworm 
Pancreatic insufficiency 
Decreased intake 
• Malnutrition 
• Reduced intake of animal products 
• Strict vegan diet 
Congenital/inherited 
• Intrinsic factor receptor deficiency/defect—Imerslund-Gräsback 
syndrome 
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• Congenital deficiency of intrinsic factor—“juvenile” pernicious 
anemia 
• Cobalamin mutation (C-G-1 gene) 
• Transcobalamin deficiency 
Increased requirements 
• Hemolysis 
• HIV 
Drugs 
• Alcohol 
• Nitrous oxide 
• Proton pump inhibitors 
• H 2 receptor antagonists 
• Metformin 
• Colchicine 
• Slow K (potassium chloride) preparations 
• Cholestyramine 
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CLINICAL FEATURES OF VITAMIN B 12 DEFICIENCY; 
The clinical manifestations of vitamin B12 deficiency represent the 
effects of depletion on multiple systems and vary greatly in severity. The 
clinical manifestations are heterogeneous but can also be different depending 
on the degree and duration of deficiency89, 90,91. 
           Mild deficiency manifests as fatigue and anemia, with indices 
suggesting  B 12 deficiency but an absence of neurological features. 
Moderate deficiency may include an obvious macrocytic anemia with, for 
example, glossitis and some mild or subtle neurological features, such as 
distal sensory impairment.  
         Severe deficiency shows evidence of bone marrow suppression, clear 
evidence of neurological features, and risk of cardiomyopathy. However, it is 
important to recognize that clinical features of deficiency can manifest 
without anemia and also without low serum vitamin B12 levels. In these 
cases treatment should still be given without delay. 
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Bone marrow 
The bone marrow is most commonly affected. Anemia may range from 
mild to severe, with symptoms of fatigue on exertion, dyspnea, palpitations, 
and pallor. All cell lines can be affected, with macrocytic anemia, low white 
cell count or neutropenia, and thrombocytopenia. 
Tissues and organ dysfunction 
           Epithelial changes with vitamin B12 deficiency include skin 
hyperpigmentation and glossitis. Reproductive tissue can be affected, 
manifesting as infertility. Deficiency can also result in osteoporosis, with 
reduced bone derived alkaline phosphatase and plasma osteocalcin. Rarely, 
cardiomyopathy can occur. 
Neurological features 
           Neurological impairment includes motor disturbances, sensory loss, 
abnormal balance and reflexes, cognitive impairment, and memory loss. 
Extreme cases may present with stupor or psychosis. An estimated 20% of 
patients with neurological signs do not manifest anemia. Clinical features of 
anemia may be minimal and the blood indices may not reflect important 
anemia. Neurological symptoms can occur in isolation so it is important to 
consider a diagnosis of vitamin B 12 deficiency in the presence of 
62 
 
neurological symptoms of unknown cause, as neurological features may 
progress and become irreversible. 
Sub-acute combined degeneration of the spinal cord involves 
demyelination of the posterior and lateral tracts. Initial bilateral peripheral 
neuropathy can progress to axonal degeneration and neuronal death if left 
untreated. This is followed by disturbances of proprioception, vibratory 
sense, and areflexia. Patients may mention clumsiness, poor coordination, 
and difficulty walking. Without treatment, weakness and stiffness may 
develop, manifesting as spastic ataxia. Damage to peripheral nerves results in 
sleepiness, altered taste and smell, and optic atrophy. In severe deficiency or 
advanced stages, a dementia-like illness may be seen, and frank psychosis 
with hallucinations, paranoia, and severe depression. 
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FIGURE 19: CLINICAL FEATURE OF VITAMIN B12 DEFICIENCY 
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TABLE 7: LABORATORY ASSESSMENT OF VITAMIN B1294,95: 
Assessment and investigation 
Mean cell volume 
FINDING 
Normal or increased 
Haemoglobin Normal or low 
Reticulocyte count Low 
Lactate dehydrogenase Increased 
Peripheral smear Anaemia, macrocytosis hyper segmented 
neutrophils (>5% of neutrophils with=5 
lobes).Neutropenia and thrombocytopenia 
Bone marrow aspirate and trephine Hyper cellular marrow, decreased 
myeloid: erythroidratio.Nuclear chromatin 
is diffuse and immature. White cells show 
megaloblastic features with large band 
forms and giant metamyelocytes. Nuclei 
may have abnormal stain appearance. 
Megakaryocytes may have increased 
nuclear lobulation or hypogranulation 
Serum/plasma cobalamin 
concentration 
Low (<150 ng/l) 
Serum/plasma holotranscobalamin 
concentration 
Low (<5 pmol/l) 
Serum/plasma or urine methyl 
malonic acid 
Increased (>350 nmol/l) 
Plasma homocysteine Raised (>15 micromol/l) 
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FIGURE 20:  
BLOOD AND BONE MARROW ASPIRATE INDICATING 
MEGALOBLASTIC ANEMIA 
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VITAMIN B 12 LEVEL; 
Vitamin B 12 level is actually a measurement of serum cobalamin. 
Measurement of vitamin B 12 in serum is the most common assay used to 
evaluate vitamin B 12 levels. The test, however, also measures both serum 
holohaptocorrin and serum holotranscobalamin, and as such may mask true 
deficiency or falsely imply a deficient state. The test is widely available at 
low cost and uses an automated method and competitive-binding immune 
chemiluminescence. The clinically normal level for serum cobalamin is not 
completely clear. It has been suggested that serum cobalamin<148 pmol/L 
(200 ng/L) would be sensitive enough to diagnose 97% of patients with 
vitamin B deficiency. It is not clear what level of serum cobalamin may 
represent subclinical deficiency. 
 
Identifying the cause of vitamin B 12 DEFICIENCY 
           Once a diagnosis of vitamin B 12 deficiency is identified, history 
taking and examination are important. If there is no obvious dietary lack of 
vitamin B or malabsorption, tests for intrinsic factor and antiparietal cell 
antibodies should be performed to exclude pernicious anemia. 
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FIGURE 21: DIAGNOSTIC ALGORITHM FOR VITAMIN B12 
DEFICIENCY 
 
PERNICIOUS ANEMIA: 
                                      Pernicious anemia is a severe megaloblastic anemia 
that results from inadequate tissue levels of vitamin B12. The underlying 
problem is a lack of intrinsic factor production by the stomach. Pernicious 
anemia is due principally to an autoimmune gastritis in which the blood 
contains antibodies against intrinsic factor and other proteins of the parietal 
cells. These antibodies damage the patient’s mucosa and abolish the secretion 
of both intrinsic factor and HC1.  
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FIGURE 22: PERNICIOUS ANEMIA 
 
(A) Intrinsic factor secreted from stomach reaches intestine.  
(B) = Vitamin B12 absorbed with the help of intrinsic factor.  
(C) = In pernicious anemia, antibody against IF is produced.  
(D) = In presence of antibody, absorption is not taking place 
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The hematological presentation of pernicious anemia is 
indistinguishable from that of folic acid deficiency. Vitamin B12 deficiency 
results in an inability to transfer the methyl group from 5-methyl-TH4 to 
homocysteine to form methionine. Since the methyl group of 5-methyl-TH4 
cannot be oxidized to 5’, 10’-methylene-TH4 or other one-carbon folate 
derivatives, the TH4 pool becomes “trapped” as 5-methyl-TH4 in vitamin B 
12-deficient persons. This, in turn, diminishes the availability of TH4 for 
nucleotide synthesis, resulting in megaloblastic anemia. With time, 
pernicious anemia can result in progressive neurological degeneration, which 
in its later stages may present with tingling or numbness of the extremities 
and diminished reflexes. Neurological damage may be due to insufficient 5’-
deoxyadenosyl-B 12 to support the methylmalonyl-CoA mutase reaction, 
resulting in a buildup of methylmalonic acid. When present at elevated 
concentrations, methylmalonyl-CoA can substitute for malonyl-CoA in fatty 
acid synthesis, leading to the synthesis of branched-chain fatty acids, which 
are incorporated into phospholipids of the myelin sheath. Alternatively, the 
neurological symptoms may be due to inadequate amounts of S-
adenosylmethionine in neural tissues. 
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TREATMENT: 
 TIMING OF TREATMENT; 
It is usually acceptable to start treatment within a few days of a 
confirmed diagnosis. If there are neurological disturbances then treatment 
should be expedited and started without delay. Specialist input should be 
sought in the event of neurological features, including impaired cognitive 
state. Neurological presentation may occur in the absence of hematological 
changes, with early treatment essential to avoid permanent neurological 
disability. Emergency treatment with packed red cell transfusion may be 
required for major anemia in the presence of cardiovascular compromise82,86. 
 
Parenteral treatment; 
           Data from randomized controlled trials and observational studies for 
parenteral treatment are lacking; however, the expert For standard treatment 
is to begin parenteral treatment with intramuscular hydroxocobalamin. This 
bypasses the possibility of the debate about whether the treatment will be 
adequately taken, absorbed, and metabolized. Standard initial treatment for 
patients without neurological involvement is 1000 µg intramuscularly three 
times a week for two weeks. If there are neurological symptoms then 1000 µg 
intramuscularly on alternate days should be continued for up to three weeks 
or until there is no further improvement. In irreversible cases, for example, 
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pernicious anemia, the treatment should be continued for life. For temporary 
causes, such as pregnancy, the treatment can be reviewed when the patient is 
fully replete and the causative agent removed. Hydroxocobalamin is 
generally well tolerated. Rarely, side effects include itching, exanthema, 
chills, fever, hot flushes, nausea, dizziness, and very rarely anaphylaxis. 
There can be a Cross over reaction to cobalamin; if there is concern about this 
then the drug should be administered in a place where hypersensitivity can be 
managed, with hydrocortisone and chlorphenramine cover available. 
 
Oral treatment; 
Cyanocobalamin is an oral preparation that can be given at a Dose of 
50-150 µg daily. The duration is determined by the causeof the deficiency. If 
the cause is irreversible then parenteral therapy should be continued for life. 
This is a drug preparation requiring conversion to metabolically active 
cobalamins. A 
Cochrane review of two randomized controlled trials in 108 people 
with vitamin B deficiency found that high oral doses of B 12 (1000 µg and 
2000 µg daily) were as effective as intramuscular treatment in achieving 
hematological and neurological responses. However, UK national consensus 
is that there are arguments against the use of oral cobalamin in severely 
deficient patients and those with malabsorption. High dose oral cobalamin 
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may be a suitable alternative in selective cases, where intramuscular 
injections are not tolerated and compliance is not a problem, as previously 
described. 
Oral treatment may be considered in certain situations—for example, 
in mild or subclinical deficiency with no clinical features and when 
absorption and compliance are definitely not a problem. 
           Treatment with vitamin B leads to the production of new Erythrocytes, 
which results in an intracellular influx of potassium. This may produce severe 
hypokalemia, which requires monitoring and appropriate treatment. 
 
PREVENTION OF VITAMIN B 12 DEFICIENCY; 
It is not currently possible to prevent vitamin B 12 deficiency from 
pernicious anemia. Deficiency due to gastric and terminal ileum disease 
should be anticipated and supplemented before clinical presentation of 
deficiency. Breakfast cereals are fortified with vitamin B 12, as a non-animal 
based dietary source. This may be useful for older people (>65 years) and 
those with a restricted diet. Each portion contains approximately 25% of the 
recommended daily intake of vitamin B 12.For patients taking long term 
metformin and proton pump inhibitors the use of oral cyanocobalamin could 
be considered, or increased screening and vigilance of vitamin B 12 
deficiency. 
  
 
 
 
MATERIALS AND METHODS 
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MATERIALS AND METHODS 
STUDY DURATION: 
This study was conducted over a period of six months. 
STUDY POPULATION: 
The study comprised of type 1 Diabetes Mellitus patients visiting the 
Outpatient department of institute of diabetology, Rajiv Gandhi government 
general hospital, Chennai.  Age and sex matched healthy volunteers served as 
controls. 
Sample Size: 
Total Number of Subjects    : 100 
Number of controls     : 50 
Number of Type 1 Diabetes Mellitus cases  : 50 
TYPE OF STUDY: 
              Observational study 
ETHICS COMMITTEE APPROVAL: 
          Obtained. 
INCLUSION CRITERIA: 
• Patients diagnosed as Type 1 Diabetes Mellitus 
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EXCLUSION CRITERIA: 
• Type 2 diabetes mellitus 
• pregnancy 
• liver disorders 
• renal failure 
• hypothyroidism 
• Patients on drugs which alters serum vitamin b 12 levels 
• Previous gastro intestinal surgery. 
• Patients with established vitamin b 12 deficiency. 
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DATA COLLECTION AND METHODS 
METHODOLOGY 
Data for the study was collected from all those who fulfilled the 
inclusion and exclusion criteria after taking a detailed case history and 
obtaining a written informed consent. 
METHOD OF COLLECTION OF DATA: 
Baseline data including age and sex, detailed medical history including 
conventional risks factors, clinical examinations and relevant investigations 
were included as part of the methodology. For all the subjects standing height 
and weight were measured. 
SPECIMEN COLLECTION: 
Blood: 
5 ml plain venous blood sample after overnight fasting was obtained by 
venipuncture for estimation of vitamin b 12 and anti-intrinsic factor anti-
bodies. For PPBS, blood sample was collected 2 hours after the breakfast. For 
HbA1C estimation 2 ml of EDTA blood sample was collected. This was 
followed by centrifugation and then sample was processed immediately after 
collection. 
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DETERMINATIONS: 
1.  Serum vitamin B 12 level by chemiluminiscence method using the 
lab cut off value of 180 pmol/l . 
2.  Glycosylated haemoglobin by immunoturbidimetric method. 
3. Fasting and post prandial blood sugars by oxidase / peroxidase 
method. 
4. Anti-intrinsic factor antibodies by chemiluminescence method. 
 
All the data will be entered in proforma(enclosed). 
The statistical software using SPSS was used for the analysis of data 
and MS word and Excel have been used to generate graphs, tables etc. 
  
  
 
 
 
OBSERVATION AND RESULTS 
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OBSERVATION AND RESULTS 
The present study was done to evaluate the prevalence of vitamin B 12 
deficiency in type 1 diabetes mellitus and try to find out cause of vitamin B12 
deficiency by determining anti-intrinsic factor antibodies. 50 cases of type 1 
diabetic cases were considered for this study and 50 age and sex matched 
healthy individuals were chosen as controls. The mean age of control and 
cases are presented in table 1A. A sex wise distribution of control and study 
groups are shown in table 1B. 
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AGE DISTRIBUTION: 
         In our study among both the cases and control group, 22 % were in the 
age group of 10-19 years,42% were in the age group of 20 -29 years ,28 % 
were in the age group of 30 -39 years and 8 % were in the age group of 40 – 
49 years. The mean age is 27.5 in both the groups. 
 
 Group numbers Mean 
Std. 
Deviation 
P value 
AGE 
( years) 
Control 50 27.50 8.021 
1.000 
Not 
significant. Cases 50 27.50 8.021 
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SEX DISTRIBUTION: 
                  In our study, among both cases and controls, 54 % were males and 
46 % were female. 
 
 
Group 
Total P value  
Control Cases 
Sex 
Male 
Count 27 27 54  
 
 
1.000 
Not 
significant 
% within Sex 50.0% 50.0% 100.0% 
% within 
Group 
54.0% 54.0% 54.0% 
Female 
Count 23 23 46 
% within Sex 50.0% 50.0% 100.0% 
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SEX DISTRIBUTION IN CASES AND CONTROLS 
 
 
 
 
 
 
Sex
FemaleMale
Co
u
n
t
28
27
26
25
24
23
22
Group
Control
Cases
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VITAMIN B 12 DEFICIENCY IN CASES AND CONTROLS: 
Among the type 1 diabetes group, 24 patients had vitamin B 12 
deficiency (< 180 pmol/l), and 26 patients had normal vitamin B 12 levels 
(>180 pmol/l). 
           Among the controls, 3 patients had vitamin B 12 deficiency (< 180 
pmol/l), and 47 patients had normal vitamin B 12 levels (>180 pmol/l). 
The correlation of vitamin B 12 levels between these groups is highly 
significant (p<0.001). 
  
Group N Mean 
Std. 
Deviation 
P value  
Vitamin B 12 
Level (pmol/l) 
Control 50 308.00 71.394 <0.001 
HIGHLY 
SIGNIFICANT 
Cases 50 227.70 75.697 
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Group Total  
Control Cases  P VALUE  
Vitamin B 
12 Level 
(pg/ml) 
<= 180 
Count 3 21 24 
<0.001 
HIGHLY 
SIGNIFICANT 
% within 
Vitamin B 
12 Level 
(pmol/l) 
12.5% 87.5% 100.0% 
% within 
Group 
6.0% 42.0% 24.0% 
> 180 
Count 47 29 76 
% within 
Vitamin B 
12 Level 
(pmol/l) 
61.8% 38.2% 100.0% 
% within 
Group 
94.0% 58.0% 76.0% 
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VITAMIN B 12 LEVELS CASES AND CONTROLS 
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VITAMIN B 12 DEFICIENCY IN CASES AND CONTROLS 
 
 
 
 
 
 
21
3
0 0
VITAMIN B 12 LEVEL (<180 pmol/L)
CASES CONTROLS
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VITAMIN B 12 DEFICIENCY IN CASES AND CONTROLS 
 
 
 
 
 
0
5
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30
35
40
45
50
cases controls
VITAMIN B 12 LEVELS IN CASES AND CONTROLS
B12 DEFICIENCY (<180 PMOL/L) NORMAL VITAMIN B12 LEVEL(>180 PMOL/L)
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ANTI INTRINSIC FACTOR ANTIBODIES IN INDIVIDUALS 
DEFICIENT IN VITAMIN B 12 (<180 pmol/L): 
Among 24 type 1 diabetes mellitus patients who were deficient in 
vitamin B 12 (<180 pmol/l), 4 patients had anti intrinsic factor antibodies. 
Among 3 individuals in the control group, who were deficient in vitamin B 
12 (<180 pmol/l), none of them had anti intrinsic factor antibodies. 
The correlation between these two groups is highly significant 
(p<0.001). 
 
 
 
 
 Group Total P VALUE  
Control Cases  
<0.001 
HIGHLY 
SIGNIFIC
ANT 
ANTI 
INTRINSIC 
FACTOR 
ANTI BODIES 
PRESENT 
Count 0 4 4 
% within 
Group 
.0% 8.0% 4.0% 
ABSENT 
Count 3 22 25 
% within 
Group 
6.0% 44.0% 25.0% 
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ANTI INTRINSIC FACTOR ANTIBODIES IN  
CASES AND CONTROLS 
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DURATION OF DIABETES AND VITAMIN B 12: 
Among the type 1 diabetes mellitus group, the mean duration of 
diabetes in those deficient in vitamin b 12 (<180 pmol/l),was 9.43 years . The 
mean duration of diabetes in years in those with normal vitamin b 12 (>180 
pmol/l) was 8.31 years. p value (0.074 was not statistically significant). 
 
Duration of 
Diabetes in 
years 
Vitamin B 12 
Level (pmol/l) 
N Mean 
Std. 
Deviation 
P VALUE  
<= 180 21 9.43 5.609 .074 
Not 
significant > 180 29 8.31 6.136 
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FASTING BLOOD SUGAR AND VITAMIN B12: 
Among the type 1 diabetes mellitus group, the mean fasting blood 
sugar in those deficient in vitamin b 12 (<180 pmol/l),was 133.14 mg /dl. The 
mean fasting blood sugar in those with normal vitamin b 12 (>180 pmol/l) 
was 144.86 mg/dl. p value (0.044 was not statistically significant). 
 
FBS (mg/dl) 
Vitamin B 
12 Level 
(pmol/l) 
N Mean 
Std. 
Deviation 
P VALUE 
<= 180 21 133.14 49.331 .044 
Not significant > 180 29 144.86 40.639 
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POST PRANDIAL BLOOD SUGAR AND VITAMIN B12: 
Among the type 1 diabetes mellitus group, the mean post prandial 
blood sugar in those deficient in vitamin b 12 (<180 pmol/l),was 218.90 mg 
/dl. The mean post prandial blood sugar in those with normal vitamin b 12 
(>180 pmol/l) was 239.76mg/dl. p value (0.093 was not statistically 
significant). 
 
PPBS 
(mg/dl) 
Vitamin B 
12 Level 
(pmol/l) 
N Mean 
Std. 
Deviation 
P VALUE 
<= 180 21 218.90 75.845 .093 
Not significant > 180 29 239.76 56.381 
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HB A 1C AND VITAMIN B12: 
Among the type 1 diabetes mellitus group, the mean HBa1c in those 
deficient in vitamin b 12 (<180 pmol/l), was 7.00. The mean HBa1c in those 
with normal vitamin b 12 (>180 pmol/l) was 6.993. P value (0.140 was not 
statistically significant). 
 
HbA1C in 
percentage 
Vitamin B 
12 Level 
(pmol/l) 
N Mean 
Std. 
Deviation 
P VALUE 
<= 180 21 7.000 .3619 
-.014 
Not significant 
> 180 29 6.993 .2618 
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DISCUSSION 
Vitamin B12, an essential micronutrient which is required for optimal 
hemopoetic, neuro-cognitive and cardiovascular function. High prevalence of 
Biochemical and clinical vitamin B12 deficiency have been demonstrated 
with type 1 and type 2 diabetes mellitus. It presents with wide range of 
clinical manifestations from   megaloblastic anaemia pancytopenia impaired 
memory, dementia, delirium, peripheral neuropathy, sub-acute combined 
degeneration of the spinal cord,  
Increased frequency of vitamin B12 deficiency among both type 
1(T1DM) and type 2 DM (T2DM) patients have been documented in several 
cross sectional studies and case reports. The prime factor associated with 
vitamin B12 deficiency among patients with T2DM is Metformin use. The 
prevalence of vitamin B12 deficiency due to metformin use range from 5.8% 
to 33%. The varied study definitions of vitamin B12 deficiency explains the 
wide variation of the reported prevalence. Pflipsen et al.  on 203 outpatient 
type 2 diabetic patients at a military primary care clinic in USA,  definite 
vitamin B12 deficiency was defined as “serum vitamin B12 concentrations of 
<100 pg/ml or elevated serum methylmalonic acid of >243 nmol/L or 
homocysteine concentrations of >11.9 nmol/L if serum vitamin B12 
concentrations were between 100 to 350 pg/ml”.  
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           In the National Health and Nutrition Examination Survey of 1999–
2006 in the USA “defined definite and borderline biochemical vitamin B12 
deficiency as serum vitamin B12 concentrations of ≤148 pmol/l and >148-
221 pmol/l respectively” .In one cross sectional study that documented a high 
prevalence of vitamin B12 deficiency of 33% among adult patients with 
T2DM vitamin B12 deficiency was defined as” serum vitamin B12 
concentrations <150 pg/ml “.patients who were on high dose (>2 g/day) and 
longterm (4 years) metformin treatment were enrolled in this study, both 
clinical factors known to be associated with vitamin B12 deficiency. 
           Comparison of the prevalence of vitamin B12 deficiency among 
T2DM patients and healthy general populations is difficult, Due to the 
diverse definitions of vitamin B12 deficiency Used in most studies and the 
cultural and religious beliefs in different regions of the world. 
           A population based study done “among 1048 elderly Finnish subjects 
aged 65–100 years, the total prevalence of definite vitamin B12 deficiency 
was 12.1% previously diagnosed vitamin B12 deficiency was reported among 
2.6% of the participants”. Vitamin B12 replacement therapy was documented 
among only 2.6% of the participants. In this study, vitamin B12 deficiency 
was defined” as total serum vitamin B12 concentrations<150 pmol/l or total 
serum vitamin B12 of 150–250 pmol/l and holotranscobalamin≤37 pmol/l 
and homocysteine≥15µmol/l.” 
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India, being a country with diverse cultural and religious beliefs, 
documented a very high prevalence of vitamin B12 deficiency among the 
general population due to its large proportion of vegetarians.  
           In one study by Yajnik et al. to determine the frequency of vitamin 
B12 deficiency and hyperhomocysteinemia among 441 healthy middle aged 
Indian men, “vitamin B12 deficiency as defined by vitamin B12 
concentrations <150 pmol/L was reported among 67% of the study 
participants” .Vegetarian diet was the sole significant factor associated with 
low vitamin B12. 
           In another cross sectional study “among 175 healthy elderly Indian 
subjects aged >60 years, vitamin B12 deficiency also defined as vitamin B12 
concentrations <150 pmol/L was reported among 16% of the study 
participants .Elevated serum MMA concentrations which are a more sensitive 
indicator of vitamin B12 deficiency were documented among 55% of the 
participants”. 
           Type 1 DM (T1DM) is “an auto immune condition that results from 
auto immune destruction of insulin secreting beta cells of the pancreas. It is 
invariably associated with other organ and non-organ specific auto immune 
and endocrine conditions leading to development of autoimmune 
polyglandular syndromes. Pernicious anemia resulting from chronic 
autoimmune gastritis is highly frequent among patients with T1DM. Chronic 
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autoimmune gastritis and pernicious anemia occurs in about 2% and up to 1% 
of the general population respectively. Among patients with T1DM, the 
prevalence is increased by 3 to 5 folds. 
           Vitamin B12 deficiency due to pernicious anemia occurs frequently 
among patients with T1DM. In one cross sectional study done in South India 
among 90 patients with T1DM, low vitamin B12 levels were noted among 
45.5% of the study subjects as defined by the manufactures’ cut off point of 
<180 pg/ml and among 54% using the published cut off point of <200 pg/ml . 
No positive correlation was noted between low vitamin B12 levels and 
gender, age, duration of DM and level of glycemic control. 
           Patients with T1DM actively exhibit auto antibodies to intrinsic factor 
(AIF) type 1 and 2 and parietal cell antibodies (PCA)  especially those with 
glutamate decarboxylase-65 (GAD-65) antibodies and HLA-DQA1*0501-
B1*0301 haplotype . The PCA inhibit secretion of intrinsic factor resulting 
into pernicious anemia, a condition which is 10 times more prevalent among 
type 1 diabetic patients than non-diabetic patients. 
            Type 1 AIF result into vitamin B12 deficiency by blocking the 
binding of vitamin B12 to IF. This prevents its transportation to its absorption 
site, the terminal ileum. These auto antibodies are found in 70% of patients 
with pernicious anemia. Primary autoimmune hypothyroidism and celiac 
disease are frequent co morbidities among patients with T1DM and directly 
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affect vitamin B12 metabolism. In one cross sectional study among 504 
ambulatory T1DM patients in South Africa, the overall prevalence of co-
existing auto immune hypothyroidism was 20.2%, especially among female 
patients (30.9% Vs 10.1%-males, p<0.0002).                      
Celiac disease in this study cohort was reported in 3 (0.6%) patients. 
Vitamin B12 deficiency among patients with autoimmune hypothyroidism 
could be explained by the presence of antibodies to the gastric parietal cells 
and intrinsic factor, reduced oral intake, dyserythropoesis due to thyroid 
hormone deficiency and defective absorption due to reduced bowel motility, 
bowel wall oedema and bacterial overgrowth .Celiac disease which is a 
highly prevalent autoimmune mediated gastrointestinal condition occurs in 1-
16% of T1DM patients compared to 0.3-1% in the general population 
.Ingestion of wheat gluten and other related proteins have been documented 
to be the trigger factors of this condition in genetically susceptible 
individuals. Due to the associated enteropathy, patients often present with 
failure to thrive, chronic diarrhea and anemia due to micronutrient (mainly 
folate, vitamin B12) malabsorption. 
Among patients with T1DM, there are no clear guidelines regarding 
screening for vitamin B12 deficiency. However, due to the high prevalence of 
pernicious anemia and subsequent vitamin B12 deficiency among T1DM 
patients reported in most cross sectional studies, it would be pragmatic to 
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screen at diagnosis and then later yearly for 3 years, then five yearly 
thereafter or in presence of any clinical indication since vitamin B12 
deficiency can develop at any time . Screening should involve assessment of 
serum vitamin B12 levels and markers of gastric autoimmunity like PCA and 
AIF especially among T1DM patients with GAD-65 and thyroid peroxidase 
antibodies. Presence of these auto antibodies increases the propensity to 
developing vitamin B12 deficiency. 
           There are no guidelines to address how often patients with T1DM and 
T2DM should be supplemented with vitamin B12. The optimal 
supplementation dose of vitamin B12 is also unknown. A recently published 
follow up study from the United States of America showed that 
administration of oral vitamin B12 among type 2 DM patients on long term 
use of metformin was ineffective in correcting biochemical vitamin B12 
deficiency .The doses of vitamin B12 in the multivitamin formulations used 
by the study subjects in this survey were probably inadequate to correct 
vitamin B12 deficiency. This stresses the need of further studies to determine 
the optimal vitamin B12 supplementation dose and frequency of 
supplementation among patients with DM. To avert vitamin B12 deficiency 
especially among adult type 2 diabetic patients on long term use of 
metformin, it is plausible to adopt a simple and cost effective 
supplementation approach in diabetes care. A 1000µg dose of vitamin B12 
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given annually would be sufficient to replenish the body’s vitamin B12 stores 
among this category of patients. 
Our study showed that the prevalence of low serum B12 in type 1 
diabetics when compared with age and sex matched controls. 42 % of type 1 
diabetes patients had low vitamin b 12 level using laboratory cut- off value of 
180 pmol/L while only 6 % of controls had low vitamin b 12 levels(<180 
pmol/l).The difference in the prevalence of low B12 levels due to different 
cut- off values used has been reported in many studies in the past. In addition, 
the lack of a gold standard complicates the diagnostic evaluations. Since 
serum B12 assays and other biomarkers such as MMA and 
holotranscobalamin lack sufficient sensitivity and specificity when used 
alone, a combination of markers along with clinical evaluation is preferred to 
define the prevalence of cobalamin deficiency. However markers such as 
MMA are expensive and not readily available in all laboratories. Hence 
serum cobalamin estimation continues to be used to assess the cobalamin 
status. The mean B12 value obtained in our study was very low (227.70 
pmol/L), when compared with controls (308 pmol/l), which was statistically 
significant .however, consistent with other reports, the deficiency was similar 
in males and females. Correlation analysis did not show any correlation 
between B12 and age, duration of diabetes, or diabetic control. The presence 
of anti-intrinsic factor antibodies in those deficient in vitamin b 12 was done. 
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Among 24 type 1 diabetes mellitus patients who were deficient in vitamin b 
12 (<180 pmol/l), 4 patients had anti intrinsic factor antibodies. Among 3 
individuals in the control group, who were deficient in vitamin b 12 (<180 
pmol/l), none of them had anti intrinsic factor antibodies, which was 
statistically significant “which stresses the fact that auto immune pathology  
for vitamin  b 12 deficiency. 
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CONCLUSIONS 
Clinical and biochemical vitamin B12 deficiency is “highly prevalent 
among patients with both types 1 and 2 DM. Future large and well-designed 
studies on screening for vitamin B12 deficiency, vitamin B12 
supplementation and optimal supplementation dose among type 1 and type 2 
diabetic patients are warranted to help guide formulation of guidelines in 
diabetes clinical care. Annual screening for vitamin B12 deficiency using 
more sensitive methods like serum homocysteine and methylmalonic acid 
concentrations (in clinical settings where they are accessible) and 
supplementation should be adopted among diabetic patients with specific risk 
factors of vitamin B12 deficiency”.  
Among 24 type 1 diabetes mellitus patients who were deficient in 
vitamin b 12 (<180 pmol/l), 4 patients had anti-intrinsic factor antibodies. 
Our study demonstrated the presence of low serum B12 levels in type  
1 diabetics. These findings merit further research on a larger population using 
additional markers to investigate into the cause of deficiency, the factors 
involved, and benefit of B12 supplementation in these patients. 
 
 
  
 
 
 
LIMITATIONS 
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LIMITATIONS OF THE STUDY 
 
• The study sample was small, and hence necessitates the need of a 
larger study with wide range of study populatipon. 
 
• Other causes of vitamin b 12 deficiency should be looked for as our 
study detected only for anti-intrinsic factor antibodies.  
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ANNEXURES 
 PATIENT DATA 
NAME: - 
AGE: -            SEX: - Male / Female 
OP No.:- 
ADDRESS: - 
CHIEF COMPLAINTS:- 
Duration of Diabetes:- 
Other complaints:- 
DRUG HISTORY:- 
PAST HISTORY:- 
FAMILY HISTORY:- 
PERSONAL HSTORY:- 
Diet: 
Habits: 
Bowel & Bladder: 
 
  
GENERAL PHYSICAL EXAMINATION:- 
Build:           Nourishment: 
Height:          Weight:      BMI: 
BP:          Pulse: 
Pallor:  P / A      Cyanosis: P / A        
Clubbing: P / A                   Edema: P / A 
Icterus:   P / A                   Lymphadenopathy: P / A 
 
SYSTEMIC EXAMINATION:- 
CVS: 
R/S: 
CNS: 
P/A: 
DIAGNOSIS: 
 
 
 
 INVESTIGATIONS: 
FBS:                           
PPBS:                                  
HbA1c: 
Vitamin b 12: 
Anti-intrinsic factor antibodies: 
 
 
 
 
 
  
 
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
  
   
INFORMATION SHEET 
We are conducting a study on ““A STUDY ON PREVELANCE OF 
VITAMIN-B 12 DEFICIENCY IN TYPE 1 DIABETES MELLITUS  AND 
ITS CAUSES” among patients attending Rajiv Gandhi Government General 
Hospital, Chennai and for that your specimen may be valuable to us. 
 
The purpose of this study is to assess the PREVELANCE OF 
VITAMIN – B 12 DEFICIENCY IN TYPE 1 DIABETES MELLITUS 
AND ITS CAUSES. 
 
We are selecting certain cases and if you are found eligible, we may be 
using your specimen to perform extra tests and special studies which in any way 
do not affect your final report or management. 
 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid in 
the management or treatment. 
 
 
 
Signature of Investigator Signature of Participant 
PATIENT CONSENT FORM 
 
Study Title : “A STUDY ON PREVELANCE OF VITAMIN-B 12 
DEFICIENCY IN TYPE 1 DIABETES MELLITUS  
AND ITS CAUSES 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
 
Name :  
 
Age/Sex :  
 
Identification Number :  
 
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to me in my 
own language 
 ❏ 
I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time without giving reason, without my legal rights being affected. 
 ❏ 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the 
ethical committee and the regulatory authorities will not need my permission to look at 
my health records, both in respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published, unless as required under the law. I agree not to restrict the 
use of any data or results that arise from this study. 
 
❏ 
I agree to take part in the above study and to comply with the instructions given during the 
study and faithfully cooperate with the study team and to immediately inform the study 
staff if I suffer from any deterioration in my health or well being or any unexpected or 
unusual symptoms. 
 ❏ 
I hereby consent to participate in this study. 
 ❏ 
I hereby give permission to undergo complete clinical examination, diagnostic tests 
including hematological, biochemical tests and radiological tests. ❏ 
 
 
Signature/ Thumb impression                                  Signature of the investigator 
 
Patient’s name and address                                        Study Investigator’s name 
 
                                                                                 Dr. B. MIDHUN KUMAR  
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